Nathalie Bardy‐Bouxin

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

Jörge E. Cortes, Carlo Gambacorti‐Passerini, Michael W. Deininger et al. · Journal of Clinical Oncology · 2017 · 493 citations · Full text

Medicine, Hematology, Pharmacotherapy +12

Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer

Stephen Chan, M. E. Scheulen, S. Johnston et al. · Journal of Clinical Oncology · 2005 · 468 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

Mario Campone, Igor Bondarenko, Stephen Brincat et al. · Annals of Oncology · 2011 · 104 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

Adil Daud, Smitha Krishnamurthi, Mansoor N. Saleh et al. · Clinical Cancer Research · 2011 · 90 citations · Full text

Medicine, Oncology, Pharmacology +17

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Andreas Hochhaus, Carlo Gambacorti‐Passerini, Camille N. Abboud et al. · Leukemia · 2020 · 83 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14